New weight loss pill approved for use in UK

• Eli Lilly has obtained UK approval for Foundayo, a new weight loss medication, expanding treatment options beyond existing GLP-1 receptor agonists like Mounjaro
• The approval represents an additional pharmacological tool for managing obesity, though clinical efficacy and safety profile compared to established agents require careful evaluation
• GPs should familiarise themselves with Foundayo's indications, patient selection criteria, and potential role in obesity management pathways as it becomes available in practice

Foundayo is made by Eli Lilly, the drug firm behind the Mounjaro jab.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.